Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
Sponsor: Peking University People's Hospital
Summary
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
260
Start Date
2024-06-20
Completion Date
2027-08-20
Last Updated
2024-04-17
Healthy Volunteers
No
Conditions
Interventions
Equecabtagene Autoleucel
Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
Locations (1)
Peking University People's Hospital
Beijing, China